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Dear Editor, 
recently in this journal Anker et al. published the trial design and baseline characteristics of 
the EMPEROR-Preserved Trial.1, 2 Compared to previous HFpEF-trials investigating 
established drugs for the treatment of heart failure with reduced ejection fraction (HFrEF), the 
mechanistic evidence of empagliflozin as a rationale for treating patients with heart failure 
with preserved ejection fraction (HFpEF) seems to be more promising. Accordingly, we 
believe that the first experimental findings in human HFrEF and HFpEF myocardium have to 
be taken in consideration in this elegant clinical trial as they pave the way for a deeper 
mechanistic understanding of potential effects of empagliflozin in the EMPEROR-Preserved 
trial. 
In this journal3, we firstly demonstrated that empagliflozin has direct diabetes-independent 
cardiac effects in human explanted hearts and biopsies. In human myocardium from patients 
with HFrEF empagliflozin reduced diastolic dysfunction without altering systolic force. 
Importantly, this could be expanded to human myocardium from patients with HFpEF by 
demonstrating that empagliflozin lowers the typical pathological diastolic stiffness due to 
improved titin phosphorylation and other small myofilamentary proteins.3 In a further study, 
we showed that these direct cardiac effects are mediated by a reduction of myocardial 
inflammation and oxidative stress upon empagliflozin in human HFpEF myocardium leading 
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The heterogeneity among HFpEF patients is high and previous trials failed to provide 
prognostic relevant treatment options for HFpEF patients. However, we noted that in the 
EMPEROR‐Preserved trial the number of patients with comorbidities associated with 
inflammation and oxidative stress (i.e. diabetes mellitus, chronic kidney disease) is higher 
compared to previous HFpEF trials.2 Our translational human in-vitro data indicate that 
empagliflozin might be useful to specifically target these mechanisms in the myocardium of 
HFpEF patients and may therefore improve diastolic function.  Utilizing human hearts with 
the disease of question is necessary to overcome the limitations of animal models. These 
translational aspects should be considered for the rationale of the EMPEROR-Preserved 
trial. 
We wish the trialists every success and hope that this study will reveal a new therapeutic 
option for a mechanistic treatment of HFpEF-patients. 
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